We speculated on whether LIAs demonstrating improved performance characteristics in comparison with ELISA can be the first test able to detect aPL assisting in the differentiation of patients with APS from asymptomatic aPL+ carriers and aPL-positive patients with infectious diseases. This evidence concerns the gene FASLG and autoimmune polyendocrinopathy.